CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder

Planned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorder

Regulatory milestone enables Company to raise up to $50 million through second closing of private placement announced September 2025